These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29676008)

  • 1. Letter: phenotype and natural history of elderly onset inflammatory bowel disease-Authors' reply.
    Mañosa M; Domènech E
    Aliment Pharmacol Ther; 2018 May; 47(10):1421-1422. PubMed ID: 29676008
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: phenotype and natural history of elderly onset inflammatory bowel disease.
    Everhov ÅH; Ludvigsson JF; Olén O
    Aliment Pharmacol Ther; 2018 May; 47(10):1420-1421. PubMed ID: 29676005
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors' reply.
    Wilson A; Jansen LE; Rose RV; Gregor JC; Ponich T; Chande N; Khanna R; Yan B; Jairath V; Khanna N; Sey M; Beaton M; McIntosh K; Teft WA; Kim RB
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1044-1045. PubMed ID: 29512906
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery? Authors' reply.
    Savoye G; Fumery M; Gower-Rousseau C
    Aliment Pharmacol Ther; 2018 Aug; 48(3):384-385. PubMed ID: 29998504
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: fulminant onset complicated inflammatory bowel disease (IBD) - a unique subtype? Authors' reply.
    Jayasooriya N; Saxena S; Pollok RC
    Aliment Pharmacol Ther; 2023 May; 57(10):1194-1195. PubMed ID: 37094302
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease and Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Authors' reply.
    Ahmed I; Greenwood R; Costello B; Ratcliffe N; Probert C
    Aliment Pharmacol Ther; 2016 Jun; 43(11):1241-2. PubMed ID: 27137729
    [No Abstract]   [Full Text] [Related]  

  • 7. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study.
    Mañosa M; Calafat M; de Francisco R; García C; Casanova MJ; Huelín P; Calvo M; Tosca J; Fernández-Salazar L; Arajol C; Zabana Y; Bastida G; Hinojosa J; Márquez L; Barreiro-de-Acosta M; Calvet X; Monfort D; Gómez-Garcia MR; Rodríguez E; Huguet JM; Rojas-Feria M; Hervias D; Atienza R; Busquets D; Zapata E; Dueñas C; Charro M; Martínez-Cerezo FJ; Plaza R; Vázquez JM; Gisbert JP; Cañete F; Cabré E; Domènech E;
    Aliment Pharmacol Ther; 2018 Mar; 47(5):605-614. PubMed ID: 29369387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease - authors' reply.
    Diederen K; Hoekman DR; Benninga MA
    Aliment Pharmacol Ther; 2016 Aug; 44(3):309-10. PubMed ID: 27375102
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: causes of fatigue in inflammatory bowel disease remain uncertain - authors' reply.
    Artom M; Czuber-Dochan W; Norton C
    Aliment Pharmacol Ther; 2017 Mar; 45(5):763-764. PubMed ID: 28150457
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter: screening for adrenal suppression in paediatric inflammatory bowel disease - authors' reply.
    Philpott H; Dougherty MK; Dellon ES
    Aliment Pharmacol Ther; 2018 Oct; 48(8):885-886. PubMed ID: 30281837
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases - authors' reply.
    Chu TPC; Grainge MJ; Card TR
    Aliment Pharmacol Ther; 2019 Feb; 49(3):346. PubMed ID: 30663105
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: validated fatigue questionnaires in inflammatory bowel diseases--authors' reply.
    Czuber-Dochan W; Norton C
    Aliment Pharmacol Ther; 2014 Feb; 39(3):342. PubMed ID: 24397324
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter: inflammatory bowel disease guidelines and conflicts of interest--authors' reply.
    Feuerstein JD; Leffler DA; Cheifetz AS
    Aliment Pharmacol Ther; 2013 Aug; 38(4):445-6. PubMed ID: 23855400
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.
    Christensen B; Gibson PR; Rubin DT
    Aliment Pharmacol Ther; 2018 May; 47(10):1423-1424. PubMed ID: 29676007
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: dermatological complications with therapy for inflammatory bowel disease--authors' reply.
    Ghosh S; Moran GW
    Aliment Pharmacol Ther; 2014 Jan; 39(2):233-4. PubMed ID: 24330245
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: combination of biologics in inflammatory bowel diseases. Authors' reply.
    Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
    Aliment Pharmacol Ther; 2020 Aug; 52(3):568-569. PubMed ID: 32656846
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter: diagnostic delay in inflammatory bowel disease-Authors' reply.
    Pollok RC; Baillie S; Jayasooriya N; Blackwell J; Petersen I; Bottle A; Saxena S;
    Aliment Pharmacol Ther; 2023 May; 57(10):1205-1206. PubMed ID: 37094317
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: risk factors and impacts of psychological morbidity in young people with inflammatory bowel disease - authors' reply.
    Brooks AJ; Rowse G; Ryder A; Peach EJ; Corfe BM; Lobo AJ
    Aliment Pharmacol Ther; 2016 Aug; 44(4):426. PubMed ID: 27413001
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.
    Mahadevan U; Vermeire S; Lasch K; Abhyankar B; Bhayat F; Blake A; Dubinsky M
    Aliment Pharmacol Ther; 2018 Aug; 48(3):388-389. PubMed ID: 29998501
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease - authors' reply.
    Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
    Aliment Pharmacol Ther; 2016 Oct; 44(7):770-1. PubMed ID: 27593429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.